AA Signature provides an innovative approach to treatment planning that focuses on patient outcomes
The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, is now also approved to aid in the assessment of HER2-ultralow status for metastatic breast cancer patients.
Datroway is the eighth new medicine of the 20 AstraZeneca has set out to deliver by 2030
If approved, sasanlimab would be the first PD-1 inhibitor, in combination with BCG, to significantly prolong event-free survival in this patient population
Infections with H. pylori affect over 43 percent of the world’s population with a wide range of gastrointestinal disorders
In the US, the compassionate use approvals are provided by FDA in the form of individual patient-specific expanded-access IND
IBRANCE is the first CDK4/6 inhibitor to show benefit in a large Phase 3 trial in first-line HR+, HER2+ metastatic breast cancer, in combination with anti-HER2 and endocrine therapy
CLL is one of the most common leukemias among adults affecting more than 200,000 people in the US
This partnership will enable healthcare organizations to provide best-in-class patient/consumer experiences
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
Subscribe To Our Newsletter & Stay Updated
